Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13458062 | 0.80 | GABRA1 (0.52) | MAPTALDH1A1HDAC4DHODHMEN1 | |
| SCHEMBL29959678 | 0.79 | RAB9A (0.50) | HDAC4DHODHMEN1KMT2ANPC1 | |
| SCHEMBL121970 | 0.79 | RAB9A (0.50) | HDAC4DHODHMEN1KMT2ANPC1 | |
| SCHEMBL8467926 | 0.78 | HDAC4 (0.46) | MAPTALDH1A1HPGDHSD17B10HDAC4 | |
| SCHEMBL3458918 | 0.78 | NPY5R (0.47) | MAPTALDH1A1HDAC4DHODHMEN1 | |
| SCHEMBL30719418 | 0.78 | HDAC4 (0.46) | MAPTALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL218007 | 0.78 | L3MBTL1 (0.49) | MAPTALDH1A1HPGDHDAC4DHODH | |
| SCHEMBL16780594 | 0.78 | HDAC4 (0.46) | MAPTALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL6850684 | 0.78 | SLC6A2 (0.49) | MAPTALDH1A1POLBHPGDHDAC4 | |
| SCHEMBL30661720 | 0.78 | L3MBTL1 (0.49) | MAPTALDH1A1HPGDHDAC4DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| CN-104761717-B | A kind of PAEK quadripolymer and preparation method thereof | 中国科学院长春应用化学研究所 | 2018-03-20 | — | — | CN | claimed |
| EP-4347571-B1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | HOFFMANN LA ROCHE (CH) | 2026-04-22 | — | — | EP | disclosed |
| CN-121873039-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2026-04-17 | — | — | CN | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| US-20250224398-A1 | GASDERMIN E EXPRESSION IN HUMAN T CELLS AS A MARKER FOR PROINFLAMMATORY T CELL FUNCTIONS | LEIBNIZ INST FUER NATURSTOFF FORSCHUNG UND INFEKTIONSBIOLOGIE E V HANS KNOELL INST HKI (DE) | 2025-07-10 | — | — | US | disclosed |
| WO-2025133307-A1 | HETEROCYCLIC MODULATORS OF THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2025-06-26 | — | — | WO | disclosed |
| CN-104725987-B | A kind of coating composition and metal material | 中国科学院长春应用化学研究所 | 2017-03-29 | — | — | CN | disclosed |
| CN-106398172-A | Wear-resistant PEAK (polyaryletherketone) material and preparation method thereof | 中国科学院长春应用化学研究所 | 2017-02-15 | — | — | CN | disclosed |
| CN-106398171-A | High-strength polyaryletherketone material with stable size and preparation method thereof | 中国科学院长春应用化学研究所 | 2017-02-15 | — | — | CN | disclosed |
| CN-101679299-A | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| CN-1937995-A | Keratin dyeing compositions comprising bicyclic 5-6 heteroaromatic dyeing compounds containing a ring-connected nitrogen atom | PROCTER & GAMBLE (US) | 2007-03-28 | — | — | CN | disclosed |
| CN-1155600-C | 2, 3-diaryl pyrazolo [1, 5-b ] pyridazine derivatives, their preparation and their use as cyclooxygenase 2 inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| CN-1278263-A | 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors | GLAXO GROUP LTD (GB) | 2000-12-27 | — | — | CN | disclosed |
| EP-1056746-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999037648-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | MAPT 931/4885ALDH1A1 2354/4885POLB 4672/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | MAPT 913/4885ALDH1A1 2869/4885POLB 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.